Intermittent claudication

被引:5
作者
Alan T. Hirsch
Laura M. Reich
机构
[1] University of Minnesota Medical School,Vascular Medicine Program, Cardiovascular Division, Minnesota Vascular Diseases Center
关键词
Clopidogrel; Peripheral Arterial Disease; Main Side Effect; Cilostazol; Main Drug Interaction;
D O I
10.1007/s11936-001-0035-4
中图分类号
学科分类号
摘要
Intermittent claudication is the most common symptom in patients with peripheral arterial disease (PAD). As such, it is mandatory for clinicians to treat both the PAD-specific symptoms (to decrease functional impairment and thereby improve quality-of-life, as well as to decrease rates of amputation) and the underlying systemic atherosclerosis (and thereby reduce cardiovascular ischemic events, especially myo-cardial infarction and stroke). Most patients with claudication can successfully decrease their exertional limb symptoms via a combination of exercise (preferably supervised) and pharmacotherapeutic interventions (eg, cilostazol). Endovascular revascularization currently serves as an effective therapy for patients with high-grade stenoses of the proximal limb arterial segments, (eg, the distal aorta, common iliac artery, or external iliac artery, and occasionally the proximal common femoral artery). Surgical revascularization usually is reserved for patients who present with severe aortoiliac disease in whom long-term patency is likely to be achieved (eg, aortobi-femoral or femoral-femoral bypass) and who have a low cardiovascular perioperative ischemic risk. Patients who undergo successful revascularization also are likely to benefit from exercise rehabilitation programs. All patients with PAD, of any severity, must successfully normalize atherosclerosis risk factors and use antiplatelet therapies. Such interventions include complete smoking cessation, glycemic control, normaliza-tion of blood pressure (less than 130/90 mm Hg), and lowering of low-density lipo-protein (LDL) cholesterol to less than 100 mg/dL. Antiplatelet agents (eg, clopidogrel, aspirin) should be prescribed to decrease rates of cardiovascular ischemic events in dall patients with PAD, unless otherwise contraindicated.
引用
收藏
页码:167 / 180
页数:13
相关论文
共 112 条
[1]  
Newman AB(1991)Lower extremity arterial disease in elderly subjects with systolic hypertension J Clin Epidemiol 44 15-20
[2]  
Sutton-Tyrell K(1993)Anklearm index as a marker of atherosclerosis in the Cardiovascular Health Study. Cardiovascular Health Study (CHS) Collaborative Research Group Circulation 88 837-845
[3]  
Rutan GH(1997)Associations of ankle-brachial index with clinical coronary heart disease, stroke and preclinical carotid and popliteal atherosclerosis: The Atherosclerosis Risk in Communities (ARIC) Study Atherosclerosis 131 115-125
[4]  
Newman AB(1995)Effect of diagnostic criteria on the prevalence of peripheral arterial disease. The San Luis Valley Diabetes Study Circulation 91 1472-1479
[5]  
Siscovick DS(1988)The evaluation of exercise performance in patients with peripheral vascular disease J Cardiopulm Rehab 12 525-532
[6]  
Manolio TA(2000)TransAtlantic Inter-Society Consensus Working Group. Management of Peripheral Arterial Disease (PAD) J Vasc Surg 31 S1-S296
[7]  
Zheng ZJ(1996)Diagnosis and treatment of chronic arterial insufficiency of the lower extremities: a critical review Circulation 94 3026-3049
[8]  
Sharrett AR(1992)Mortality over a period of 10 years in patients with peripheral arterial disease N Engl J Med 326 381-386
[9]  
Chambless LE(1993)Decreased ankle/arm blood pressure index and mortality in elderly women JAMA 279 497-498
[10]  
Hiatt WR(1969)Ankle systolic pressure measurements in arterial disease affecting the lower extremities Br J Surg 56 676-679